ViferaXS Raises €12M to Advance CLL Phase II Trial
TÜBINGEN, Germany — September 23, 2026 ViferaXS GmbH announced the close of a Series A financing round of up...
HUMA
Advertisement
Humacyte FDA Accepts IND for First-in-Human CTEV CABG Study
DURHAM, N.C., July 27, 2026 Humacyte, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Advertisement
